In the United States Clostridium difficile or "C.
difficile" is now recognized as one of the most dangerous and fastest
growing Healthcare Acquired Infections (HAIs) in existence. Now
surpassing even Staphylococcus aureus (MRSA), C. difficile
infections tripled between 2000 and 2005 (http://shea.confex.com/shea/2010/webprogram/Paper2801.html).
BioMed Protect, LLC has announced the introduction of EPA-registered
Sanotracin RTU™ ("RTU" meaning ready to use), the effective and
affordable surface disinfectant with a three-minute C. difficile
spore claim at 99.9999 percent- the fastest efficacy in the
industry. Recognized as "the point of protection," patented
Sanotracin RTU is proven safe and cost effective with a verified
umatched efficacy rate as a bactericide, virucide, tuberculocide,
fungicide and sporicidal disinfectant cleaner.
Sanotracin RTU is a hospital-grade disinfectant cleaner for use in all
healthcare facilities, including surgical and obstetrical suites,
patient rooms, physical therapy departments, nursing services, autopsy
facilities and nursing homes.
More importantly, Sanotracin RTU provides sporicidal effectiveness without
the use of bleach (http://voices.yahoo.com/bleach-health-dangers-effectiveness-3068416.html).
In addition to being the only product with a three-minute efficacy
claim, Sanotracin RTU also contains no alcohol, does not
require rinsing and leaves no film on surfaces to which it is applied,
unlike many competing disinfectants with bleach.
Sanotracin RTU provides environmental services directors and front-line
environmental services staff the fastest-acting product to clean and
disinfect surfaces exposed to C. difficile spores with maximum
efficacy. "As hospitals and healthcare facilities become more efficient
in handling HAIs they need the tools and processes in place to provide
healthy spaces for patients," said Mark Regna CHESP. Sanotracin RTU
disinfectant provides a one-step process to disinfect, eliminate and
prevent the spread of C. difficile spores, MRSA, VRE Acinetobacter
baumannii and 50 other pathogens.
According to the Centers for Disease Control (CDC), C. difficile infections
are linked to 14,000 deaths in the United States each year. Deaths
related to C. difficile increased 400% between 2000 and 2007, due
in part to a stronger bacterial strain. Most C. difficile infections
are contracted by individuals while in the process of receiving medical
care. More than 90 percent of deaths occur in people 65 and older (http://www.cdc.gov/hai/organisms/cdiff/Cdiff-patient.html